Why the FDA didn’t grant an approval to Lilly’s Alzheimer’s drug By: MarketWatch January 20, 2023 at 09:23 AM EST The regulator wants to see clinical data from at least 100 patients who have taken donanemab for a year Read More >> Related Stocks: Biogen Idec Eli Lilly
